www.fdanews.com/articles/98258-novelos-therapeutics-receives-5th-u-s
Novelos Therapeutics Receives 5th U.S.
September 10, 2007
Novelos Therapeutics, a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos was issued U.S. Pat. No. 7,169,412 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos’ lead compound in pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment (SPA) and fast track.
Business Wire